Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

FDA grants Armata Breakthrough Therapy designation for AP-SA02

Armata Pharmaceuticals (NYSE American: ARMP) has announced that the FDA has granted Breakthrough Therapy designation to AP-SA02, its intravenously administered Staphylococcus aureus multi-phage product candidate, for...

September 14, 2026

Developments

Perspective and Merck collaborate on study of combined therapies in FAP-α solid tumors

Perspective Therapeutics (NYSE American: CATX) has announced a clinical trial collaboration agreement with Merck (NYSE: MRK) to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda...

September 14, 2026

Developments

Q32 Bio names Drs. José Trevejo as CMO and Ellie Hershberger as CDO

Q32 Bio (NASDAQ: QTTB) has announced the appointment of José Trevejo, MD, PhD, as chief medical officer (CMO) and Ellie Hershberger, PharmD, as chief development officer (CDO). Prior to joining Q32 Bio, Dr. Trevejo...

September 14, 2026

Developments

Eloxx announces first patients dosed in study of exaluren in NMAS

Eloxx Pharmaceuticals (NASDAQ: ELOX) has announced that the first two patients have been dosed in its Phase 2b EXACT Study evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS). According to...

September 11, 2026

Developments

First AUD patients enrolled in Clearmind’s psychedelic-based treatment trial

Clearmind Medicine (NASDAQ: CMND) has announced the enrollment of the first patients with alcohol use disorder (AUD) in its ongoing clinical trial evaluating CMND-100, the company’s proprietary psychedelic-based...

September 11, 2026

Markets

Titan starts Profound Medical at buy; PT $12

Titan Partners initiated coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with a “buy” rating and price target of $12.00. The stock closed at $5.96 on Sept 10. Profound is a commercial-stage medical device company...

September 11, 2026

Developments

IMUNON enters CRADA with NCI to advance gene-based immunotherapy

IMUNON (NASDAQ: IMNN) has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to support further clinical and non-clinical development of IMNN-001, the...

September 10, 2026

Developments

MolDX issues Bionano proposed LCD

Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics (NASDAQ: BNGO) has announced that MolDX, a program that assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors...

September 10, 2026

Developments

Ocumetics initiates patient recruitment for next-gen lens study

Ocumetics Technology (TSXV: OTC; OTCQB: OTCFF; FRA: 2QBO) has announced that its clinical facility in Mexico City has initiated the patient recruitment process for Group Two of the company’s ongoing human clinical...

September 8, 2026

Developments

eXoZymes selects Curia as CDMO for NCT

eXoZymes (NASDAQ: EXOZ) has entered into an agreement with closely held contract research, development, and manufacturing organization (CDMO) Curia Global to initiate technology transfer and scale-up activities for N...

September 8, 2026

Executive Moves

Chris Benecchi joins Inventiva as COO

Inventiva (Euronext Paris and NASDAQ: IVA) has announced the appointment of biopharmaceutical leader Chris Benecchi as chief operating officer (COO). Mr. Benecchi brings 30 years of biopharmaceutical leadership across...

September 2, 2026

Developments

Polyrizon completes site contracts for NASARIX first-in-human allergy study

Polyrizon (NASDAQ: PLRZ) has completed contracting with the fourth and fifth U.S. clinical sites participating in its study of NASARIX Allergy Blocker (PL-14), moving the program into study execution. The planned first...

September 2, 2026

Subscribe